WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319896
Description: Radiprodil, also known as RGH-896, is an orally active and selective NMDA receptors antagonist which was evaluated as potential treatmen of neuropathic pain associated with diabetic peripheral neuropathy (DPNP). Treatment with radiprodil did not show statistically significant or clinically meaningful reductions in mean daily pain scores, the primary endpoint, compared to placebo for any of the dosages studied. Based on preclinical pharmacology Radiprodil was a potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions.
MedKoo Cat#: 319896
Chemical Formula: C21H20FN3O4
Exact Mass: 397.1438
Molecular Weight: 397.4064
Elemental Analysis: C, 63.47; H, 5.07; F, 4.78; N, 10.57; O, 16.10
Synonym: RGH-896; RGH896; RGH 896; Radiprodil
IUPAC/Chemical Name: 2-(4-((4-Fluorophenyl)methyl)piperidin-1-yl)-2-oxo-N-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide
InChi Key: GKGRZLGAQZPEHO-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)
SMILES Code: O=C(NC1=CC=C2NC(OC2=C1)=O)C(N3CCC(CC4=CC=C(F)C=C4)CC3)=O
1: Fernandes A, Wojcik T, Baireddy P, Pieschl R, Newton A, Tian Y, Hong Y,
Bristow L, Li YW. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor
open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol.
2015 Nov 5;766:1-8. doi: 10.1016/j.ejphar.2015.08.044. Epub 2015 Aug 29. PubMed
2: Michel A, Downey P, Van Damme X, De Wolf C, Schwarting R, Scheller D.
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral
6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of
Non-Dopaminergic Drugs. PLoS One. 2015 Aug 31;10(8):e0135949. doi:
10.1371/journal.pone.0135949. eCollection 2015. PubMed PMID: 26322641; PubMed
Central PMCID: PMC4555651.
3: Michel A, Downey P, Nicolas JM, Scheller D. Unprecedented therapeutic
potential with a combination of A2A/NR2B receptor antagonists as observed in the
6-OHDA lesioned rat model of Parkinson's disease. PLoS One. 2014 Dec
16;9(12):e114086. doi: 10.1371/journal.pone.0114086. eCollection 2014. PubMed
PMID: 25513815; PubMed Central PMCID: PMC4267740.